AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...

Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

WILMINGTON, Del., January 17, 2025--AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with ...

The FDA also granted approval to AstraZeneca’s another BTK inhibitor Calquence in combination with standard-of-care chemoimmunotherapy for previously untreated mantle cell lymphoma. The approval ...

Jennifer A. Woyach, MD, has been named the new director of the division of hematology at The Ohio State University ...

AstraZeneca chief executive Pascal Soriot ... Imfinzi (durvalumab), PARP inhibitor Lynparza (olaparib), and Calquence (acalabrutinib) for leukaemia. Daiichi Sankyo-partnered HER2 drug Enhertu ...